{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-043726","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.971391+00:00","generated_at":"2026-06-29T13:56:53.961631+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ikena Oncology Q2 2021 net loss $12.7M; cash $264M, IK-412 IND delayed by supply","bullets":["Cash and cash equivalents $264.0M as of June 30, 2021; expected to fund operations through 2023.","Net loss $12.7M in Q2 2021 vs $5.0M in Q2 2020; R&D expense $11.4M vs $6.3M.","IK-930 IND submission on track for end of 2021; preclinical data at EORTC-NCI-AACR conference.","IK-175 monotherapy expansion cohort enrolling additional bladder cancer patients; clinical data planned in 2022.","IK-412 IND submission delayed due to shortage of a component required for COVID-19 vaccines."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-043726","json":"https://secwatch.observer/filing/0001564590-21-043726.json","markdown":"https://secwatch.observer/filing/0001564590-21-043726.md","text":"https://secwatch.observer/filing/0001564590-21-043726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000156459021043726/0001564590-21-043726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000156459021043726/ikna-8k_20210812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:56:53.961631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}